Clinical Trial Update: Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial results for gene transfer in X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating gammaretroviral vector have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency

Drugs mentioned

• Self-inactivating gammaretroviral vector

Snippet

Sponsor: David Williams | Conditions: Severe Combined Immunodeficiency | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-04-21